Navigation Links
Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Association's 69th Scientific Sessions
Date:6/1/2009

- Late-Breaking Abstract Accepted -

SAN DIEGO, June 1, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that a late-breaking abstract of its lorcaserin Phase 3 BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management) trial has been accepted for a poster presentation at the American Diabetes Association's 69th Scientific Sessions in New Orleans, Louisiana. The abstract, titled "Lorcaserin Reduces Body Weight in Obese and Overweight Subjects: Behavioral Modification and Lorcaserin for Overweight and Obesity Management, the BLOOM Trial," will be displayed from June 6, 2009 at 10:00 a.m. Central Daylight Time (CDT) until June 8, 2009 at 4:00 p.m. CDT in the Morial Convention Center, Hall E. The poster has been assigned presentation number 96-LB in category 20-B Obesity - Clinical Treatment.

Steven R. Smith, M.D., BLOOM Co-Principal Investigator and Professor and Assistant Director for Clinical Research at the Pennington Biomedical Research Center; William R. Shanahan, M.D., Arena's Vice President and Chief Medical Officer; and Christen M. Anderson, M.D., Ph.D., Arena's Vice President, Clinical Development, will be available at the poster to discuss and address questions during two periods:

- Sunday, June 7, 2009: 6:30-7:45 p.m. CDT

- Monday, June 8, 2009: 12:00-2:00 p.m. CDT

About Lorcaserin

Lorcaserin is a novel single agent that represents the first in a new class of selective serotonin 2C receptor agonists. The serotonin 2C receptor is located in areas of the brain involved in the control of appetite and metabolism, such as the hypothalamus. Stimulation of this receptor is strongly associated with feeding behavior and satiety. Lorcaserin is currently being evaluated in a Phase 3 program expected to enroll approximately 7,800 patients and potentially represents a targeted treatment option for the millions of patients who need to better manage their weight. Arena has patents that cover lorcaserin in the US and other jurisdictions, which in most cases are capable of continuing into 2023 without taking into account any patent term extensions or other exclusivity Arena might obtain.

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for weight management. Arena's broad pipeline of novel compounds target G protein-coupled receptors, an important class of validated drug targets, and includes compounds being evaluated independently and with partners, including Merck & Co., Inc., and Ortho-McNeil-Janssen Pharmaceuticals, Inc.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about lorcaserin's potential to be the first in a new class of agonists or treatment option; lorcaserin's selectivity; enrollment in the lorcaserin Phase 3 program; lorcaserin's patent coverage; and Arena's strategy, internal and partnered programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, Arena's ability to obtain additional funds; the timing, success and cost of Arena's lorcaserin program and other of its research and development programs; results of clinical trials or preclinical studies may not be predictive of future results; clinical trials and studies may not proceed at the time or in the manner Arena expects or at all; Arena's ability to partner lorcaserin or other of its compounds or programs; the timing and ability of Arena to receive regulatory approval for its drug candidates; Arena's ability to obtain and defend its patents; and the timing and receipt of payments and fees, if any, from Arena's collaborators. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

    Contacts:           Jack Lief
                        President and Chief Executive Officer

                        Cindy McGee
                        Senior Communications Associate

                        Arena Pharmaceuticals, Inc.
                        858.453.7200, ext. 1479


'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
2. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
6. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
7. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
8. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
9. Critical Pharmaceuticals Enter Sustained Release hGH Arena
10. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
11. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... PHILADELPHIA , March 30, 2017  Lannett Company, ... the company voluntarily made a $25 million payment against ... $25 million payment, combined with the $75 million payment ... us approximately $5.5 million in annualized cash interest expense, ... executive officer of Lannett.  "Our business is solid and ...
(Date:3/29/2017)... Research and Markets has announced the addition of the ... (Insource IONM, Outsource IONM), By Region And Trend Analysis From ... ... Intraoperative Neuromonitoring (IONM) market is expected to reach USD 3.6 ... witness significant growth in the forecast period, which can be ...
(Date:3/29/2017)... NEW YORK , March 29, 2017 Global ... cross US$ 3 billion by 2021, growing at a CAGR ... containing iron prescribed by a doctor to treat anemia or ... the iron level in the body. However, in some cases, ... in the body and intravenous (IV) iron therapy comes into ...
Breaking Medicine Technology:
(Date:3/30/2017)... ... ... inventor and manicurist from Greet, S.C., wants to offer people a new way to care ... and healthy feet, so I know the importance of proper foot care," he said. "In ... FOOT-TRAN SYSTEM." , The FOOT-TRAN SYSTEM enables a user to clean and exfoliate the bottoms ...
(Date:3/30/2017)... ... 30, 2017 , ... This morning, more than 275 medical ... support for an independent Vaccine Safety Commission. Five of the signers of the ... hold a press conference at 9:00 AM Friday, March 31 at the ...
(Date:3/29/2017)... San Diego, CA (PRWEB) , ... March 29, 2017 , ... ... meningiomas(1,2), and up to 300,000 people each year develop other types of metastatic brain ... spread quickly throughout the brain(3). As efforts focus on finding more effective treatment options, ...
(Date:3/29/2017)... ... ... main cause of hay fever in the United States, with an estimated 95 percent of ... July each year; with the worst time for sufferers being June and July. , ... provide an effective defense against grass pollen; they are proven in independent studies to trap ...
(Date:3/29/2017)... ... March 30, 2017 , ... Sublime Naturals and its ... Life" or "Wonder Spice", it has been used for thousands of years. , "The ... says Heshelow, author of " Turmeric: How to Use it For Your Wellness. Overcome ...
Breaking Medicine News(10 mins):